Stock comparison
DexCom
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
DXCM
DexCom
Market cap
$27.82B
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Overall winner
DexCom DXCM
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | DXCM | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 69B | 65C | DXCM |
| Benjamin Graham | 74B | 64C | DXCM |
| Philip Fisher | 75B | 48D | DXCM |
| Peter Lynch | 61C | 25F | DXCM |
| Joel Greenblatt | 58C | 76B | GMAB |
| Charlie Munger | 66B | 68C | GMAB |
| Terry Smith | 66B | 71C | GMAB |
Side-by-side metrics
| Metric | DXCM | GMAB |
|---|---|---|
| Market cap | $27.82B | $16.5B |
| P/E (TTM) | 24.6x | 6.2x |
| EV/EBIT | 25.4x | 12.0x |
| ROIC (TTM) | 18.03% | 43.78% |
| Gross margin | 61.84% | 93.88% |
| Net margin | 19.31% | 18.23% |
| Revenue CAGR 5y | 17.47% | -18.45% |
| EPS CAGR 5y | 39.82% | -23.48% |
| Debt / Equity | 0.5x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
DXCM leads on
- Revenue CAGR 5y17.47%vs -18.45%+195%
- EPS CAGR 5y39.82%vs -23.48%+159%
- Market cap$27.82Bvs $16.5B+41%
- Net margin19.31%vs 18.23%+6%
GMAB leads on
- Debt / Equity0.1xvs 0.5x+84%
- P/E (TTM)6.2xvs 24.6x+75%
- ROIC (TTM)43.78%vs 18.03%+59%
- EV/EBIT12.0xvs 25.4x+53%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.